Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 9/20 | 0.38 |
| ▸ | KLK1 | P06870 | 8/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044136 | 0.86 | ALDH1A1 (0.54) | IDH1ALDH1A1HPGDKLKB1KLK1 | |
| SCHEMBL5048726 | 0.86 | SREBF2 (0.46) | IDH1ALDH1A1KLKB1 | |
| SCHEMBL5044978 | 0.84 | KLKB1 (0.49) | IDH1ALDH1A1HPGDKLKB1KLK1 | |
| SCHEMBL5048649 | 0.82 | IDH1 (0.49) | IDH1ALDH1A1HPGDKLKB1MEN1 | |
| SCHEMBL5047884 | 0.82 | CDC25A (0.45) | IDH1ALDH1A1HPGDKLKB1MEN1 | |
| SCHEMBL5039436 | 0.80 | ALDH1A1 (0.58) | IDH1ALDH1A1HPGDKLKB1KLK1 | |
| SCHEMBL5048621 | 0.79 | KLKB1 (0.48) | IDH1ALDH1A1HPGDKLKB1KLK1 | |
| SCHEMBL5047149 | 0.79 | ALDH1A1 (0.42) | IDH1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL5049135 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HPGDKLKB1KLK1MEN1 | |
| SCHEMBL5043787 | 0.78 | ALDH1A1 (0.51) | IDH1ALDH1A1HPGDKLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | IDH1 3182/4885ALDH1A1 959/4885HPGD 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.